HKD 0.17: 0708.HK China Evergrande NEV on HKSE oversold bounce setup: watch volume
The 0708.HK stock is trading at HKD 0.17 intraday on the HKSE after heavy turnover of 162,856,795.00 shares, presenting a classic oversold bounce setup. Price sits below the 50-day average of HKD 0.18 and well under the 200-day average of HKD 0.26, signalling short-term mean-reversion potential. Traders watching an oversold bounce should focus on a rising volume confirmation and any corporate updates from China Evergrande New Energy Vehicle Group Limited that could reverse the intraday price direction. We present key metrics, technical triggers, and risk-managed price targets for Hong Kong investors.
Intraday price action and setup for 0708.HK stock
China Evergrande New Energy Vehicle Group Limited (0708.HK) opened at HKD 0.17 and has traded between HKD 0.17 and HKD 0.21 today. The stock shows a one-day change of +1.19% and a relative volume near 4.99x the average, driven by a spike in orders. For an oversold bounce strategy, we watch a sustained uptick above the 50-day average HKD 0.18 and a close above HKD 0.20 on volume to validate a short-term reversal.
Fundamental snapshot tied to the bounce thesis for 0708.HK stock
Fundamentals are weak: EPS is -2.61, and the trailing PE is negative at -0.07. Market cap stands at HKD 1,843,444,864.00 with 10,843,793,317 shares outstanding. Cash per share is modest at HKD 0.01 and the current ratio is 0.34, well below the Healthcare sector average of 3.65. These numbers temper any long-term optimism but do not negate a technical bounce opportunity for short-term traders.
Technical indicators and triggers for a short-term rebound in 0708.HK stock
Key technicals: price is below the 50-day (HKD 0.18) and 200-day (HKD 0.26) moving averages. Average daily volume is 32,634,888.00; today’s 162,856,795.00 indicates fresh participation. For an entry, we recommend waiting for a 30-minute close above HKD 0.19 with rising volume. Protect with a tight stop under HKD 0.15. RSI and MACD readings are currently muted in delayed feeds, so use price and volume as primary triggers.
Meyka AI rating and risk assessment for 0708.HK stock
Meyka AI rates 0708.HK with a score out of 100: 60.54 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s negative margins, large working-capital deficits, and negative book value raise structural risk. For traders, the bounce trade is tactical; for investors, capital preservation and position sizing should reflect high volatility and weak fundamentals.
Valuation, comparable sector context and key risks for 0708.HK stock
Price-to-sales is about 1.22 while EV/sales is elevated at 21.13, reflecting accounting and balance-sheet distortions. Compared with the Hong Kong Healthcare sector average PE of 29.06, 0708.HK’s negative PE highlights earnings challenges. Key risks: group-level credit exposure, prolonged negative free cash flow, and very high receivables days. Upside catalysts for an oversold bounce include confirmed liquidity support or better-than-expected segment updates from new-energy or healthcare operations.
Short-term price targets and a trading plan for 0708.HK stock
For a controlled oversold bounce trade we outline three price targets: conservative HKD 0.22, base HKD 0.28, and aggressive HKD 0.45. Stop-loss should be sized to risk no more than 2%–3% of total capital per position, with a hard stop at HKD 0.15. Watch order flow and any company announcements; a confirmed volume breakout toward HKD 0.22 would validate the first target and reduce downside probability.
Final Thoughts
Short-term traders can treat the 0708.HK stock move at HKD 0.17 as an oversold bounce opportunity, but the setup requires strict risk controls. Meyka AI’s technical read points to a volume-led mean reversion chance if price clears HKD 0.19–0.20 on strong turnover. Meyka AI’s forecast model projects a near-term base case of HKD 0.28, implying an upside of 64.71% versus the current HKD 0.17. Conservative profit-taking at HKD 0.22 secures gains and limits exposure; an extended rally to HKD 0.45 would need positive fundamental news. Forecasts are model-based projections and not guarantees. Given negative EPS (-2.61), thin cash buffers and an impaired balance sheet, longer-term investors should treat any rebound as tactical and size positions for high volatility. For intraday trading on the HKSE, confirm entries with volume and keep stops tight.
FAQs
Is 0708.HK stock a buy on this oversold bounce?
An oversold bounce can offer short-term trades, but 0708.HK stock has weak fundamentals and negative EPS. Use a tight stop and small position size. For long-term buy decisions, wait for clearer balance-sheet repairs and earnings improvement.
What short-term price targets should traders use for 0708.HK stock?
Traders can use staged targets: HKD 0.22 (conservative), HKD 0.28 (base) and HKD 0.45 (aggressive). Confirm moves with rising volume and protect capital with stops under HKD 0.15.
How does sector performance affect 0708.HK stock outlook?
Healthcare peers show healthier liquidity and margins. 0708.HK’s current ratio of 0.34 is far below the sector average 3.65, increasing risk. Sector strength may help sentiment but does not offset company-specific issues.
Where can I find company filings and updates for 0708.HK stock?
Primary sources are the company site and HKSE announcements. Start with the company website for corporate updates: China Evergrande Health.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)